142 related articles for article (PubMed ID: 33445214)
21. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
22. [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases].
Rammeh-Rommani S; Mokni M; Stita W; Trabelsi A; Hamissa S; Sriha B; Tahar-Yacoubi M; Korbi S
J Gynecol Obstet Biol Reprod (Paris); 2005 Oct; 34(6):568-71. PubMed ID: 16208199
[TBL] [Abstract][Full Text] [Related]
23. Mitotically active leiomyomas of the uterus.
Prayson RA; Hart WR
Am J Clin Pathol; 1992 Jan; 97(1):14-20. PubMed ID: 1728856
[TBL] [Abstract][Full Text] [Related]
24. Mitotically active leiomyomas of the uterus.
O'Connor DM; Norris HJ
Hum Pathol; 1990 Feb; 21(2):223-7. PubMed ID: 2307449
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience of uterine smooth muscle tumor of uncertain malignant potential in two gynecological centers: Oncological and obstetrical aspects.
Shim JI; Han AKW; Jeon HJ; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Cho YJ; Rha SH
Eur J Obstet Gynecol Reprod Biol; 2020 Mar; 246():7-13. PubMed ID: 31927240
[TBL] [Abstract][Full Text] [Related]
26. Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential.
Conconi D; Chiappa V; Perego P; Redaelli S; Bovo G; Lavitrano M; Milani R; Dalprà L; Lissoni AA
Oncol Rep; 2017 Jan; 37(1):41-47. PubMed ID: 28004108
[TBL] [Abstract][Full Text] [Related]
27. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
[TBL] [Abstract][Full Text] [Related]
28. A clinicopathologic study of uterine smooth muscle tumours of uncertain malignant potential (STUMP).
Ng JS; Han A; Chew SH; Low J
Ann Acad Med Singap; 2010 Aug; 39(8):625-8. PubMed ID: 20838704
[TBL] [Abstract][Full Text] [Related]
29. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
30. ["STUMP" (smooth muscle tumour of uncertain malignant potential), a tumour of the uterus in pregnancy--a diagnostic and therapeutic challenge].
Clauss S; Höller S; Hegi L; Blum R; Hösli I
Z Geburtshilfe Neonatol; 2010 Apr; 214(2):74-7. PubMed ID: 20411475
[TBL] [Abstract][Full Text] [Related]
31. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
32. Atypical uterine leiomyoma: a case report and review of the literature.
Manxhuka-Kerliu S; Kerliu-Saliu I; Sahatciu-Meka V; Kerliu L; Shahini L
J Med Case Rep; 2016 Jan; 10():22. PubMed ID: 26801982
[TBL] [Abstract][Full Text] [Related]
33. Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases.
Perrone T; Dehner LP
Am J Surg Pathol; 1988 Jan; 12(1):1-8. PubMed ID: 3337336
[TBL] [Abstract][Full Text] [Related]
34. PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Huang LC; Ye JC; Hsieh CH; Chen LM; Lin TY; Hung YC; Chang WC
Eur J Gynaecol Oncol; 2011; 32(5):496-9. PubMed ID: 22053660
[TBL] [Abstract][Full Text] [Related]
35. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
36. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors.
Evans HL; Chawla SP; Simpson C; Finn KP
Cancer; 1988 Nov; 62(10):2239-47. PubMed ID: 3179938
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases.
Kurman RJ; Norris HJ
Cancer; 1976 Apr; 37(4):1853-65. PubMed ID: 56982
[TBL] [Abstract][Full Text] [Related]
38. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): A single center experience.
Karataşlı V; Çakır İ; Ayaz D; Budak A; Sancı M
J Gynecol Obstet Hum Reprod; 2019 Oct; 48(8):637-642. PubMed ID: 30898630
[TBL] [Abstract][Full Text] [Related]
40. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
